Recent Advances in Adjuvant Endocrine Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer

Abstract

are accepted on a 12-month basis. Prices are subject to change without notice. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription rate are on a prorated basis. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability.